| __timestamp | Agios Pharmaceuticals, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 18516000 |
| Thursday, January 1, 2015 | 141827000 | 34140000 |
| Friday, January 1, 2016 | 220163000 | 51872000 |
| Sunday, January 1, 2017 | 292681000 | 71772000 |
| Monday, January 1, 2018 | 341324000 | 97501000 |
| Tuesday, January 1, 2019 | 410894000 | 118590000 |
| Wednesday, January 1, 2020 | 367470000 | 169802000 |
| Friday, January 1, 2021 | 256973000 | 192507000 |
| Saturday, January 1, 2022 | 279910000 | 199563000 |
| Sunday, January 1, 2023 | 288903000 | 253598000 |
| Monday, January 1, 2024 | 301286000 |
Unlocking the unknown
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Agios Pharmaceuticals, Inc. and Xencor, Inc. have been at the forefront of this race since 2014. Over the past decade, Agios has consistently outpaced Xencor in R&D investment, peaking in 2019 with a 41% higher expenditure than its 2014 levels. However, Xencor has shown remarkable growth, increasing its R&D spending by over 1,270% from 2014 to 2023. This surge reflects Xencor's strategic focus on expanding its research capabilities. By 2023, the gap between the two companies had narrowed significantly, with Xencor's R&D expenses reaching 88% of Agios's. This trend highlights the dynamic nature of the biotech industry, where strategic investments in innovation can rapidly alter competitive landscapes.
Comparing Innovation Spending: Pfizer Inc. and Agios Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Xencor, Inc.
R&D Insights: How GSK plc and Xencor, Inc. Allocate Funds
Insmed Incorporated vs Xencor, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Alkermes plc vs Agios Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Xencor, Inc.
Veracyte, Inc. vs Xencor, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: ACADIA Pharmaceuticals Inc. vs Xencor, Inc.
R&D Spending Showdown: Protagonist Therapeutics, Inc. vs Xencor, Inc.
Mesoblast Limited or Agios Pharmaceuticals, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Agios Pharmaceuticals, Inc. vs MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.